Nixon Peabody Trust Co. Buys 228 Shares of Amgen Inc. (NASDAQ:AMGN)

Nixon Peabody Trust Co. grew its stake in Amgen Inc. (NASDAQ:AMGN) by 19.5% during the 1st quarter, Holdings Channel.com reports. The firm owned 1,400 shares of the medical research company’s stock after acquiring an additional 228 shares during the period. Nixon Peabody Trust Co.’s holdings in Amgen were worth $436,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently modified their holdings of the company. Centricity Wealth Management LLC bought a new position in shares of Amgen in the fourth quarter valued at about $25,000. Pinney & Scofield Inc. bought a new position in Amgen during the fourth quarter worth about $26,000. Ritter Daniher Financial Advisory LLC DE increased its position in Amgen by 66.2% during the fourth quarter. Ritter Daniher Financial Advisory LLC DE now owns 128 shares of the medical research company’s stock worth $33,000 after acquiring an additional 51 shares during the period. Synergy Investment Management LLC bought a new position in Amgen during the fourth quarter worth about $34,000. Finally, Atala Financial Inc bought a new position in Amgen during the fourth quarter worth about $34,000. 76.50% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

AMGN has been the topic of a number of recent research reports. Wells Fargo & Company reaffirmed an “equal weight” rating on shares of Amgen in a research report on Wednesday, February 5th. Piper Sandler lowered their price target on shares of Amgen from $329.00 to $328.00 and set an “overweight” rating on the stock in a research report on Friday, May 16th. Bank of America raised their price target on shares of Amgen from $275.00 to $294.00 and gave the stock an “underperform” rating in a research report on Wednesday, March 5th. Morgan Stanley reaffirmed an “equal weight” rating on shares of Amgen in a research report on Friday, May 2nd. Finally, Erste Group Bank lowered shares of Amgen from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 8th. Two analysts have rated the stock with a sell rating, twelve have given a hold rating, nine have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, Amgen currently has an average rating of “Hold” and an average price target of $309.22.

Amgen Trading Up 0.4%

AMGN opened at $289.57 on Wednesday. The company’s 50 day moving average is $282.79 and its 200-day moving average is $285.30. Amgen Inc. has a 1-year low of $253.30 and a 1-year high of $346.85. The company has a current ratio of 1.26, a quick ratio of 0.95 and a debt-to-equity ratio of 9.62. The company has a market cap of $155.70 billion, a P/E ratio of 38.35, a PEG ratio of 2.63 and a beta of 0.51.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Thursday, May 1st. The medical research company reported $4.90 earnings per share for the quarter, beating analysts’ consensus estimates of $4.18 by $0.72. Amgen had a net margin of 12.24% and a return on equity of 176.32%. The company had revenue of $8.15 billion for the quarter, compared to the consensus estimate of $8.05 billion. During the same period last year, the company posted $3.96 EPS. The firm’s quarterly revenue was up 9.4% compared to the same quarter last year. Equities research analysts predict that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.